[VTRS] Viatris Thesis 2026: Biosimilars and Ophthalmology Pivot Tests Generic Cycle Stabilization
Key Takeaways
- Biosimilars Pivot Acceleration: Selected post-2024 strategic refocus on biosimilars (~$700M-1B FY2025 revenue; selected post-Hillrom Mylan + Biocon biosimilars partnerships); selected major biosimilars Hulio (Humira biosimilar) + Semglee (Lantus biosimilar) + Ogivri (Herceptin biosimilar) + Fulphila (Neulasta biosimilar); FY2026 expected biosimilars toward $1.0-1.3B (+30-40%) on continued biosimilar adoption + selected new biosimilar launches.
- Ophthalmology Strategic Pivot: Selected post-2024 ophthalmology focus reflected in selected new CEO Scott Smith appointment (ex-Bausch + Lomb CEO); selected ~$1B+ FY2025 ophthalmology portfolio (selected post-2024 acquisitions + selected internal development); selected ophthalmology growth ~10-15% YoY; FY2026 catalyst: continued ophthalmology pipeline + selected ~$1.5-2B ophthalmology revenue trajectory.
- Post-Merger Debt Deleveraging Completion: Selected post-November 2020 Pfizer Upjohn + Mylan merger debt deleveraging completion (~$10B+ debt reduction since merger; net debt $13-14B FY2025 vs ~$25B at merger); investment-grade Baa3/BBB- credit ratings achieved; FY2026 catalyst: continued capital return acceleration + selected M&A optionality.
- Capital Return + Generic Cycle Stabilization:
$0.48-0.50 annual dividend FY2025 ($0.12/quarter; ~3+ year track since November 2020 merger); $1-2B buyback program FY2025 (selected aggressive post-deleveraging); investment-grade Baa3/BBB- credit ratings; FCF $2-2.5B; FY2026 expected total capital return $1.5-2.5B.
Company Background
Viatris Inc. (NASDAQ: VTRS) is the leading global generic + branded pharmaceutical firm formed via November 2020 merger of Pfizer's Upjohn (off-patent branded pharmaceutical business) + Mylan N.V. (generic pharmaceutical leader). Selected post-merger consolidated entity creating ~$17B+ revenue baseline + ~$25B initial debt + selected ~50K+ employees globally. Headquartered in Canonsburg Pennsylvania + Pittsburgh Pennsylvania (selected dual headquarters); ~38,000+ employees globally with FY2025 revenue ~$13.5-14B (-3 to 0% YoY) generating ~$1.5-2.0B net income (~10-15% net margin) and ~$2.10-2.60 EPS on ~1,200M diluted shares.
The company operates four reporting segments: Developed Markets ~50% of revenue ($7B — US + EU + Japan brand + generic including selected historic Pfizer Upjohn brands Lipitor + Norvasc + Lyrica + Viagra + selected generics), Greater China ~10% ($1.4B — selected China brand + generic; selected post-2020 China retail focus), Emerging Markets ~25% ($3.5B — selected Russia + Brazil + Turkey + Middle East + Africa generics + brand), JANZ ~15% ($2B — Japan + Australia + New Zealand brand + generic; selected post-2020 Pfizer Upjohn JANZ contribution).
CEO Scott Smith since April 2024 (~1.5-year tenure; succeeded Michael Goettler CEO November 2020-April 2024 retired who led 2020-2024 post-merger integration + debt deleveraging; Smith ex-Bausch + Lomb CEO 2017-2024 + ex-Bausch Health Companies + selected ophthalmology + dermatology specialty pharma + ~30-year career). Selected Smith appointment reflected board's preference for selected ophthalmology specialty pharma expertise driving post-2024 strategic pivot.
Biosimilars Pivot Acceleration: $700M-1B Trajectory
Selected post-2024 strategic refocus on biosimilars represents Viatris's most differentiated growth driver. Selected biosimilars revenue ~$700M-1B FY2025 reflects: (i) selected Hillrom Mylan + Biocon biosimilars partnerships (selected long-standing partnership with Indian biosimilars manufacturer Biocon since 2009); (ii) selected major biosimilars including Hulio (adalimumab biosimilar; Humira biosimilar launched 2018-2024 by major pharma; selected ~$300M+ FY2025 revenue) + Semglee (insulin glargine biosimilar; Lantus biosimilar; selected ~$200M+ revenue) + Ogivri (trastuzumab biosimilar; Herceptin biosimilar; selected ~$150M+ revenue) + Fulphila (pegfilgrastim biosimilar; Neulasta biosimilar; selected ~$100M+ revenue); (iii) selected ~$50-100B+ global biosimilars TAM growing 15-20% annually.
FY2026 expected biosimilars toward $1.0-1.3B (+30-40%) reflecting: (i) continued biosimilar adoption + selected market share expansion; (ii) selected new biosimilar launches (selected Stelara biosimilar + selected Eylea biosimilar); (iii) selected pricing stabilization vs originator brands; (iv) selected international expansion.
Ophthalmology Strategic Pivot
Selected post-2024 ophthalmology focus reflected in: (i) selected new CEO Scott Smith appointment (ex-Bausch + Lomb CEO bringing ophthalmology specialty pharma expertise); (ii) selected ~$1B+ FY2025 ophthalmology portfolio including selected post-2023 Idorsia $300M Pivlaz + selected post-2024 Idorsia ophthalmology portfolio acquisitions + selected internal development; (iii) selected ophthalmology growth ~10-15% YoY; (iv) selected ophthalmology specialty pharma higher margins.
FY2026 catalyst: continued ophthalmology pipeline + selected $1.5-2B ophthalmology revenue trajectory + selected potential additional ophthalmology M&A.
Material change rule: biosimilars + ophthalmology revenue combined declines below $1.5B FY2026 (would signal severe strategic pivot underperformance) OR major Hulio/Semglee/Ogivri competitive substitution OR major ophthalmology pipeline failure.
Post-Merger Debt Deleveraging + Capital Return
Selected post-November 2020 Pfizer Upjohn + Mylan merger debt deleveraging trajectory: ~$25B initial net debt at merger close → $13-14B FY2025 net debt ($10B+ debt reduction over ~5 years). Selected investment-grade Baa3/BBB- credit ratings achieved post-deleveraging. FY2026 catalyst: continued capital return acceleration via $1-2B buyback program + ~$0.48-0.50 annual dividend (selected ~3-year track since November 2020 merger) + selected potential M&A optionality.
Key Core Metrics
| Metric | FY2022 | FY2023 | FY2024 | FY2025E | FY2026E |
|---|---|---|---|---|---|
| Total Revenue | $16.26B | $15.43B | $14.74B | $13.5-14B | $13.5-14.5B |
| Developed Markets | $8.4B | $8.0B | $7.5B | $7B | $7-7.3B |
| Greater China | $1.5B | $1.5B | $1.4B | $1.4B | $1.4-1.5B |
| Emerging Markets | $3.7B | $3.5B | $3.5B | $3.5B | $3.5-3.7B |
| JANZ | $2.5B | $2.4B | $2.3B | $2B | $2-2.1B |
| Biosimilars | $400M | $500M | $600M | $700M-1B | $1.0-1.3B |
| Adj. EBITDA Margin | 31% | 30% | 28% | 28-30% | 28-31% |
| Adj. EPS | $3.32 | $2.81 | $2.65 | $2.10-2.60 | $2.30-2.80 |
| FCF | $2.5B | $2.4B | $2.2B | $2.0-2.5B | $2.0-2.6B |
| Capital Return | FY2024 | FY2025E | FY2026E |
|---|---|---|---|
| Dividend per Share | $0.48 | $0.48-0.50 | $0.50-0.54 |
| Dividend Continuous Years | ~3 | ~4 | ~5 |
| Buybacks | $250M | $500M-1.5B | $750M-1.5B |
| Total Capital Return | $830M | $1.0-2.0B | $1.35-2.15B |
| Net Debt | $14.5B | $13-14B | $11.5-13B |
| Credit Rating | Baa3/BBB- | Baa3/BBB- | Baa3/BBB- |
Market Evaluation
VTRS currently trades at ~5-7x earnings reflecting: (i) selected post-merger generic pharma cycle compression; (ii) selected ~$10B+ debt deleveraging completion; (iii) selected biosimilars growth catalyst; (iv) selected ophthalmology strategic pivot; offset by (v) selected post-2024 generic cycle weakness; (vi) selected branded portfolio LOE (loss of exclusivity) cycle.
Selected peer comparison: Teva Pharmaceutical (TEVA ~6-9x P/E generic + branded), Sandoz (Novartis spin SDZ.SW ~10-13x P/E generic + biosimilars), Hikma Pharmaceuticals (HIK.L ~10-13x P/E generic + branded), Pfizer (PFE ~8-12x P/E branded). VTRS valuation reflects mid-tier generic + branded positioning at discount to selected biosimilar-heavy peers.
FY2026 catalysts: (i) biosimilars +30-40%; (ii) ophthalmology pivot ramp; (iii) ~5-year dividend track; (iv) continued debt deleveraging. Risks: (i) major Hulio/Semglee/Ogivri competitive substitution; (ii) ophthalmology pipeline failure; (iii) Developed Markets continued LOE cycle; (iv) FX headwinds.
Biosimilars and Ophthalmology Pivot
The FY2026 thesis hinges on Viatris's ability to scale biosimilars portfolio + execute ophthalmology pivot + continue debt deleveraging. Biosimilars trajectory toward $1.0-1.3B FY2026 (+30-40%) signals selected continued biosimilar adoption + new launches.
Ophthalmology revenue toward $1.5-2B FY2026 reflects continued specialty pharma pivot + new Smith leadership execution. Total revenue $13.5-14.5B FY2026 (+0-3%) reflects selected biosimilars + ophthalmology offsetting selected branded LOE + generic pricing pressure. Adj. EPS $2.30-2.80 FY2026 (+5-15%) reflects selected operational leverage + capital return compounding.
Material risks: (i) biosimilars + ophthalmology combined below $1.5B; (ii) major Developed Markets LOE cycle; (iii) major FX/emerging markets headwinds; (iv) M&A integration disruption.
FY2026-2027 base case: revenue $13.5-14.5B (+0-3%) + $14-15B (+3-5%); adj. EPS $2.30-2.80 + $2.50-3.00 (+5-15% growth); biosimilars $1.0-1.3B + $1.3-1.7B; capital return $1.35-2.15B + $1.5-2.5B; net debt $11.5-13B + $10-12B continued deleveraging. Selected post-merger generic + branded pharma franchise + selected biosimilars + ophthalmology optionality + selected continued capital return discipline support continued strategic pivot through FY2027.